BMS 986495
Alternative Names: BMS-986495Latest Information Update: 11 Sep 2024
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neurodegenerative disorders
Most Recent Events
- 09 Aug 2024 Phase-I clinical trials in Neurodegenerative disorders (unspecified route), prior to August 2024 (Bristol Myers Squibb pipeline, August 2024)